Yuan Zhang

Yuan Zhang

Auto-generated profile, based on publicly available information

Yuan Zhang

Department of Medical Administration, Huizhou Institute of Occupational Diseases Control and Prevention, Huizhou, Guangdong, 516000, People’s Republic of China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2024 in Journal of Inflammation Research
Verified
Journal Article
Open access
PDF file
CKChen Kong
Chen Kong
MYMeifeng Yang
Meifeng Yang
NYNingning Yue
Ningning Yue
YZYuan Zhang
Yuan Zhang
CTChengmei Tian
Chengmei Tian
DLDefeng Li
Defeng Li
The intestinal barrier maintained by various types of columnar epithelial cells, plays a crucial role in regulating the interactions between the intestinal contents (such as the intestinal microbiota), the immune system, and other components. Dysfunction of the intestinal mucosa is a significant pathophysiological mechanism and clinical manifestation of inflammatory bowel disease (IBD). However, current therapies for IBD primarily focus on suppressing inflammation, and no disease-modifying treatments specifically target the epithelial barrier. Given the side effects associated with chronic immunotherapy, effective alternative therapies that promote mucosal healing are highly attractive. In this review, we examined the function of intestinal epithelial barrier function and the mechanisms of behind its disruption in IBD. We illustrated the complex process of intestinal mucosal healing and proposed therapeutic approaches to promote mucosal healing strategies in IBD. These included the application of stem cell transplantation and organ-like tissue engineering approaches to generate new intestinal tissue. Finally, we discussed potential strategies to restore the function of the intestinal barrier as a treatment for IBD.

4 April 2023 in Stem Cells International
Verified
Journal Article
Open access
PDF file
CTCheng-Mei Tian
Cheng-Mei Tian
MYMei-Feng Yang
Mei-Feng Yang
HXHao-Ming Xu
Hao-Ming Xu
MZMin-Zheng Zhu
Min-Zheng Zhu
YZYuan Zhang
Yuan Zhang
DLDefeng Li
Defeng Li
As double membrane-encapsulated nanovesicles (30-150 nm), exosomes (Exos) shuttle between different cells to mediate intercellular communication and transport active cargoes of paracrine factors. The anti-inflammatory and immunomodulatory activities of mesenchymal stem cell (MSC)-derived Exos (MSC-Exos) provide a rationale for novel cell-free therapies for inflammatory bowel disease (IBD). Growing evidence has shown that MSC-Exos can be a potential candidate for treating IBD. In the present review, we summarized the most critical advances in the properties of MSC-Exos, provided the research progress of MSC-Exos in treating IBD, and discussed the molecular mechanisms underlying these effects. Collectively, MSC-Exos had great potential for cell-free therapy in IBD. However, further studies are required to understand the full dimensions of the complex Exo system and how to optimize its effects.

1 November 2024 in Journal of Inflammation Research
Verified
Journal Article
Open access
PDF file
NYNingning Yue
Ningning Yue
PHPeng Hu
Peng Hu
CTChengmei Tian
Chengmei Tian
CKChen Kong
Chen Kong
HZHailan Zhao
Hailan Zhao
LWlisheng wang
lisheng wang
The intestinal immune system is the largest immune organ in the human body. Excessive immune response to intestinal cavity induced by harmful stimuli including pathogens, foreign substances and food antigens is an important cause of inflammatory diseases such as celiac disease and inflammatory bowel disease (IBD). Although great progress has been made in the treatment of IBD by some immune-related biotherapeutic products, yet a considerable proportion of IBD patients remain unresponsive or immune tolerant to immunotherapeutic strategy. Therefore, it is necessary to further understand the mechanism of immune cell populations involved in enteritis, including dendritic cells, macrophages and natural lymphocytes, in the steady-state immune tolerance of IBD, in order to find effective IBD therapy. In this review, we discussed the important role of innate and adaptive immunity in the development of IBD. And the relationship between intestinal immune system disorders and microflora crosstalk were also presented. We also focus on the new findings in the field of T cell immunity, which might identify novel cytokines, chemokines or anti-cytokine antibodies as new approaches for the treatment of IBD.

1 September 2025 in Journal of Inflammation Research
Verified
Journal Article
Open access
PDF file
CTCheng-Mei Tian
Cheng-Mei Tian
MYMei-Feng Yang
Mei-Feng Yang
CKChen Kong
Chen Kong
DLDuo Luo
Duo Luo
NYNing-Ning Yue
Ning-Ning Yue
DLDefeng Li
Defeng Li
The brain and gastrointestinal tract are closely interconnected as important sensory organs processing signals from both environmental and internal cues. Recent studies have shown that dysregulation of the gut microbiota in inflammatory bowel disease activates the gut immune system. The cross-talk mechanism along the gut-brain axis is implicated in the development of neuropsychiatric disorders such as autism, depression, anxiety, Alzheimer’s disease, and Parkinson’s disease. Here, we discuss the molecular mechanisms involved in signaling across the gut-brain axis, including the immune and neuroendocrine system, intestinal permeability, microbial composition, and bacterial extracellular vesicles. We focus on the link between specific inflammatory bowel disease, microbial genera and psychiatric and neurological disorders, and propose that the results of preclinical and clinical studies open up the possibility of targeting the gut microbiota to treat neuropsychiatric disorders that are altered by gut interactions. Plain Language Summary: There is a strong bidirectional communication between the brain and the digestive system. Dysregulation of the gut microbiota (GM) in inflammatory bowel disease (IBD) activates the gut immune system and contributes to brain disorders. Targeting the gut-brain axis has the potential to treat both neurological disorders such as depression, autism, Alzheimer’s disease, and Parkinson’s syndrome, and to ameliorate intestinal disorders such as IBD.

1 July 2025 in Journal of Inflammation Research
Verified
Journal Article
Open access
PDF file
YZYuan Zhang
Yuan Zhang
LHLongbin Huang
Longbin Huang
NYNingning Yue
Ningning Yue
ZMZhiliang Mai
Zhiliang Mai
CKChen Kong
Chen Kong
DLDefeng Li
Defeng Li
Background: Although cytokines have been implicated in the development of ulcerative colitis (UC), the potential mediating role of metabolite levels in this association remains unclear. Methods: Utilizing data from genome-wide association studies (GWAS) encompassing 91 circulating cytokines, 1400 blood metabolites, and 178,689 UC cases, we performed a two-sample Mendelian randomization (MR) analysis to investigate the effect of metabolites mediated cytokines on the development of UC. A two-step MR analysis was conducted to quantitatively evaluate the mediation effect. Additionally, dextran sodium sulfate (DSS)-induced colitis mice were used to further confirm our results. Results: Mendelian randomization (MR) analysis indicated that macrophage colony-stimulating factor (M-CSF) had a causal and positive relationship with aconitate (OR: 1.10, 95% CI: 1.00– 1.20, p = 0.043, IVW beta 1 = 0.095). Moreover, MR analysis revealed that high level of aconitate were associated with reduced risk of UC (OR: 0.44, 95% CI: 0.24– 0.80, p = 0.008, IVW beta 2 = − 0.818). In addition, MR analysis showed M-CSF had an inverse correlation with the disease onset of UC (OR: 0.31, 95% CI: 0.15– 0.80, p = 0.002, IVW beta all = − 1.16). Furthermore, the mediation effect of aconitate mediated M-CSF on the risk of UC was − 0.0777 (95% CI: − 0.154 to − 0.0018, p = 0.045), accounting for 6.69% of the total effect, and indicating a modest contribution to the protective effect of M-CSF against UC. Subsequently, as an in vivo validation model, DSS-induced colitis was employed to demonstrate that M-CSF treatment significantly ameliorated weight loss, disease activity index (DAI) scores, colon shortening, and histological damage. Additionally, M-CSF treatment also significantly reduced M1 macrophage infiltration, elevated levels of aconitate as well as itaconate, and decreased the levels of pro-inflammatory cytokines in colitis. These results demonstrated that aconitate inhibited the expression of pro-inflammatory cytokines through its enzymatic conversion into the immunometabolite itaconate by aconitate decarboxylase 1 (Acod1), and downregulated the levels of M1 macrophages, thereby ameliorating colitis. Conclusion: These findings suggest that M-CSF is an important anti-inflammatory cytokine in UC, which may be a promising therapeutic target in the treatment of UC.

1 September 2026 in Journal of Inflammation Research
Verified
Journal Article
Open access
PDF file
LHLong-Bin Huang
Long-Bin Huang
CKChen Kong
Chen Kong
MYMei-Feng Yang
Mei-Feng Yang
SZShuang Zhang
Shuang Zhang
NYNing-Ning Yue
Ning-Ning Yue
DLDe-Feng Li
De-Feng Li
Background: Inflammatory bowel disease (IBD) remains difficult to manage in a substantial proportion of patients because conventional systemic therapies may fail to achieve sufficient drug accumulation at inflamed intestinal sites while causing systemic adverse effects. Therefore, localized delivery systems capable of protecting therapeutic agents during gastrointestinal transit and releasing them at disease sites are urgently needed. Natural polymer-based hydrogels have attracted increasing attention because of their biocompatibility, biodegradability, mucoadhesiveness, and tunable responsiveness to intestinal pathological cues. Main Body: This review focuses on natural polymer-based hydrogels for localized therapy in IBD. We first summarize the major drug-loading strategies, including physical encapsulation, diffusion/permeation, covalent bonding, and electrostatic interaction, as well as key release mechanisms, including stimulus-responsive, diffusion-controlled, swelling-controlled, and chemically controlled release. We then systematically discuss six widely studied natural polymer-based hydrogel systems—gelatin, hyaluronic acid, alginate, chitosan, cellulose, dextran, and their derivatives. Particular attention is given to how material composition, network architecture, and disease-responsive properties influence drug protection, mucosal retention, colon-targeted release, anti-inflammatory activity, and intestinal barrier repair. Representative preclinical and translational studies are reviewed to compare the advantages and limitations of these systems. We also highlight major formulation and translation challenges, including batch variability, insufficient mechanical stability, burst release, limited targeting precision, unpredictable in vivo degradation, and scalable manufacturing. Conclusion: Natural polymer-based hydrogels provide a promising platform for localized IBD therapy by integrating biocompatible materials with controllable drug loading and disease-responsive release. Future progress will depend on disease-driven material design, rational integration of multi-responsive or composite hydrogel systems, rigorous evaluation in physiologically relevant models, and scalable manufacturing strategies. These advances may facilitate the clinical translation of personalized and locally acting hydrogel therapies for IBD.